Search
pasireotide; pasireotide diaspartate (Signifor)
Indications:
- treatment of Cushing's disease
- treatment of acromegaly [3]
Dosage:
- subcutaneous injection twice daily
Adverse effects:
- hyperglycemia
- diarrhea
- nausea
- abdominal pain
- gallstones
Mechanism of action:
- somatostatin analog
General
endocrine agent
Database Correlations
PUBCHEM correlations
References
- FDA News Release: Dec. 14, 2012
FDA approves Signifor, a new orphan drug for Cushing's disease
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332351.htm
- Novartis: Media releases
Novartis drug Signifor gains FDA approval as the first
medication to treat Cushing's disease, a serious endocrine
disorder.
http://www.novartis.com/newsroom/media-releases/en/2012/1665290.shtml
- Colao A, Bronstein MD, Freda P et al
Pasireotide versus octreotide in acromegaly: a head-to-head
superiority study.
J Clin Endocrinol Metab. 2014 Mar;99(3):791-9.
PMID: 24423324 Free PMC Article